Jim Cramer Blesses a Caller’s Speculative Investment in Xeris Biopharma
Key takeaways
- Jim Cramer Blesses a Caller’s Speculative Investment in Xeris Biopharma Syeda Seirut Javed Fri, June 12, 2026 at 9:45 PM GMT+7 1 min read XERS Xeris Biopharma Holdings, Inc.
- I know it because it’s injectables… But I will tell you this: that’s precisely what I want you to do.
- (NASDAQ:XERS) develops therapies for chronic endocrine and neurological diseases, including treatments for severe hypoglycemia, primary periodic paralysis, and endogenous hypercortisolemia.
Jim Cramer Blesses a Caller’s Speculative Investment in Xeris Biopharma Syeda Seirut Javed Fri, June 12, 2026 at 9:45 PM GMT+7 1 min read XERS Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) was among the stocks Jim Cramer commented on, saying that tech stocks cannot be trusted to lead anymore. When a caller mentioned that XERS is their speculative investment, Cramer said:
I know it because it’s injectables… But I will tell you this: that’s precisely what I want you to do. That’s precisely what you need. But one of them, just one that takes care of all the jonesing you’re doing with speculation. None of that 2, 3x, and the leverage and stuff. Just one spec will do it for you. I like that attitude.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) develops therapies for chronic endocrine and neurological diseases, including treatments for severe hypoglycemia, primary periodic paralysis, and endogenous hypercortisolemia. In addition, it is developing a once-weekly subcutaneous injection for hypothyroidism, which is currently undergoing a phase 3 clinical trial.